LXEO
Lexeo Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$4.89
+1.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 654.0K |
| Cost of Revenue | 546.0K | — | — | — | — |
| Gross Profit | (546.0K) | — | — | — | 654.0K |
| Operating Expenses | |||||
| R&D Expense | 66.6M | 63.8M | 74.1M | 53.1M | 49.2M |
| SG&A Expense | 28.5M | 45.5M | 31.7M | 15.4M | 12.0M |
| General & Admin Expense | 28.5M | 45.5M | 31.7M | 15.4M | 12.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (546.0K) | — | — | — | — |
| Total Operating Expenses | 94.6M | 109.3M | 105.8M | 68.5M | 61.2M |
| Cost and Expenses | 95.1M | 109.3M | 105.8M | 68.5M | 61.2M |
| Operating Income (EBIT) | (95.1M) | (109.3M) | (105.8M) | (68.5M) | (60.5M) |
| Non-Operating | |||||
| Interest Income | 8.0M | 6.1M | 7.6M | 2.9M | 1.3M |
| Interest Expense | 138.0K | 206.0K | 114.0K | 205.0K | 91.0K |
| Net Interest Income | 7.9M | 5.9M | 7.4M | 2.7M | 1.2M |
| Other Non-Op Income/Expense | 7.9M | 9.3M | 7.4M | 2.1M | 1.2M |
| Non-Operating Income (excl Interest) | (8.0M) | (9.5M) | (7.6M) | (2.3M) | (1.3M) |
| EBT (Pre-Tax Income) | (87.3M) | (100.0M) | (98.3M) | (66.4M) | (59.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (87.3M) | (100.0M) | (98.3M) | (66.4M) | (59.3M) |
| Earnings from Cont. Ops | (87.3M) | (100.0M) | (98.3M) | (66.4M) | (59.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (87.3M) | (100.0M) | (98.3M) | (66.4M) | (59.3M) |
| Per Share | |||||
| Basic EPS | ($1.15) | ($1.86) | ($3.09) | ($2.49) | ($2.36) |
| Diluted EPS | ($1.15) | ($1.86) | ($3.09) | ($2.49) | ($2.40) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.03 |
| Shares | |||||
| Basic Shares Outstanding | 85.6M | 53.6M | 31.8M | 26.6M | 25.2M |
| Diluted Shares Outstanding | 85.6M | 53.6M | 31.8M | 26.6M | 25.2M |
| Profitability Metrics | |||||
| EBITDA | (85.4M) | (97.7M) | (96.2M) | (64.3M) | (58.0M) |
| D&A | 1.7M | 2.1M | 2.0M | 1.8M | 1.1M |
| EBIT | (87.1M) | (99.8M) | (98.2M) | (66.2M) | (59.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026